metformin has been researched along with Fatty Liver in 166 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Fatty Liver: Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
Excerpt | Relevance | Reference |
---|---|---|
"Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD." | 9.17 | Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. ( Fan, H; Pan, Q; Xu, Y; Yang, X, 2013) |
" Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3." | 9.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
"The presence of fatty liver per ultrasound and liver-associated enzymes were measured in a select cohort of youth with both obesity and insulin resistance, and the effect of metformin on these parameters evaluated." | 9.14 | Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. ( Ehlers, LB; Love-Osborne, K; Nadeau, KJ; Zeitler, PS, 2009) |
"No significant differences between treatment with metformin or placebo were observed for changes in liver steatosis, assessed either histologically or by CT, NAS-score, liver transaminases or on markers of insulin resistance or inflammation." | 9.14 | Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. ( Birkeland, K; Bjøro, K; Eggesbø, HB; Haaland, T; Haukeland, JW; Konopski, Z; Løberg, EM; Raschpichler, G; von Volkmann, HL, 2009) |
"Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated." | 9.11 | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005) |
"To examine the effect of metformin treatment during ischemia/reperfusion injury in fatty liver and determine the possible mechanisms." | 7.96 | Metformin Attenuates Ischemia-reperfusion Injury of Fatty Liver in Rats Through Inhibition of the TLR4/NF-κB Axis ( Huang, C; Li, X; Wang, L; Yang, X, 2020) |
"Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders." | 7.91 | Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. ( Adeshirlarijaney, A; Chassaing, B; Gewirtz, AT; Tran, HQ; Zou, J, 2019) |
" This study investigated the effects of scopoletin on hepatic steatosis and inflammation in a high-fat diet fed type 1 diabetic mice by comparison with metformin." | 7.85 | Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice. ( Cho, HW; Choi, MS; Choi, RY; Ham, JR; Kim, MJ; Lee, HI; Lee, J; Lee, MK; Park, SK; Seo, KI, 2017) |
"We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 7.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
" To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity." | 7.80 | Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014) |
"To investigate the potential preventive effects of metformin on non-alcoholic fatty liver disease (NAFLD) and roles of phospholipase A2/lysophosphatidylcholine pathway in hepatocyte lipoapoptosis in a rat NAFLD model induced by high-fat diet." | 7.77 | [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes]. ( Fu, JF; Huang, Y; Liu, LR; Shi, HB, 2011) |
" Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study." | 7.77 | Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. ( Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S, 2011) |
"To report a case of idiosyncratic hepatotoxicity associated with metformin in the treatment of type 2 diabetes with nonalcoholic fatty liver disease (NAFLD)." | 7.76 | Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. ( Bachyrycz, AM; Cone, CJ; Murata, GH, 2010) |
"Our aim was to evaluate effects of metformin, rosiglitazone, and diet with exercise in nonalcoholic fatty liver disease." | 7.74 | The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. ( Aksoy, N; Akyüz, F; Beşişik, F; Boztaş, G; Cakaloğlu, Y; Cevikbaş, U; Demir, K; Ibrişim, D; Kaymakoğlu, S; Mungan, Z; Okten, A; Ozdil, S; Poturoğlu, S, 2007) |
"A 2-hour oral glucose tolerance test (OGTT) and a rapid intravenous glucose tolerance test (IVGTT) were performed before treatment was initiated, after treatment with metformin and at the end of 1 year of combination therapy with metformin and rosiglitazone to calculate quantitative insulin sensitivity check index (QUICKI) and acute insulin response (AIR)." | 7.74 | Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. ( Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S, 2007) |
"To explore the therapeutic effects of metformin on rat fatty livers induced by high fat feeding." | 7.73 | [Study on therapeutic effects of metformin on rat fatty livers induced by high fat feeding]. ( Dong, H; Gao, ZQ; Lu, FE; Wang, KF; Xu, LJ; Zhou, X, 2005) |
"To investigate the effects of metformin on fatty livers in insulin-resistant rats." | 7.73 | [Effects of metformin on fatty liver in insulin-resistant rats]. ( Chen, SQ; Deng, JC; Liu, Q; Sun, H; Tang, L, 2005) |
"To assess whether treatment with insulin-sensitizing agents (ISAs) in combination with ezetimibe and valsartan have greater effect on hepatic fat content and lipid peroxidation compared to monotherapy in the methionine choline-deficient diet (MCDD) rat model of non-alcoholic fatty liver disease (NAFLD)." | 7.73 | Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. ( Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S, 2006) |
"Metformin treatment was associated with significant decrease in PWV and AI in NAFLD patients." | 6.76 | Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. ( Boaz, M; Mashavi, M; Matas, Z; Shargorodsky, M; Sofer, E, 2011) |
" Interventions Daily dosing of 800 IU of vitamin E (58 patients), 1000 mg of metformin (57 patients), or placebo (58 patients) for 96 weeks." | 6.76 | Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. ( Abrams, SH; Brunt, EM; Chalasani, N; Clark, JM; Hoofnagle, JH; Kleiner, DE; Lavine, JE; Molleston, JP; Murray, KF; Robuck, PR; Rosenthal, P; Sanyal, AJ; Scheimann, AO; Schwimmer, JB; Tonascia, J; Ünalp, A; Van Natta, ML, 2011) |
"Insulin resistance is a major feature of type 2 diabetes mellitus, obesity and nonalcoholic fatty liver disease (NAFLD)." | 6.74 | The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. ( Gedik, O; Nar, A, 2009) |
"Metformin is an antidiabetic drug used widely in clinical practice." | 6.48 | Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease. ( Barbero-Becerra, VJ; Chavez-Tapia, NC; Mendez-Sanchez, N; Santiago-Hernandez, JJ; Uribe, M; Villegas-Lopez, FA, 2012) |
"Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan." | 6.43 | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006) |
"Metformin alone reduced hyperinsulinemia and circulating c-reactive protein, but exacerbated nephropathy." | 5.72 | Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice. ( Calcutt, NA; Doty, R; Flurkey, K; Harrison, DE; Koza, RA; Reifsnyder, PC, 2022) |
"Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models." | 5.72 | Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022) |
"Metformin was treated daily for 14 weeks in a high-fat dieting C57BL/6J mice." | 5.43 | Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21. ( Byun, JK; Cho, ML; Choi, JY; Jeong, JH; Jhun, JY; Kim, EK; Kim, JK; Lee, SH; Lee, SY, 2016) |
"Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes." | 5.38 | Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012) |
"There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease." | 5.31 | Metformin reverses fatty liver disease in obese, leptin-deficient mice. ( Chuckaree, C; Diehl, AM; Kuhajda, F; Lin, HZ; Ronnet, G; Yang, SQ, 2000) |
"Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD." | 5.17 | Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. ( Fan, H; Pan, Q; Xu, Y; Yang, X, 2013) |
" Weight, body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) index as well as serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), insulin, total and direct bilirubin, fasting blood sugar (FBS), glycated hemoglobin (HbA1c), uric acid, albumin and lipid profile were evaluated at baseline and at the end of trial." | 5.16 | Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. ( Beiraghdar, F; Ghamarchehreh, ME; Jalalian, HR; Panahi, Y; Sahebkar, A; Zare, R, 2012) |
" Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3." | 5.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
"The presence of fatty liver per ultrasound and liver-associated enzymes were measured in a select cohort of youth with both obesity and insulin resistance, and the effect of metformin on these parameters evaluated." | 5.14 | Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. ( Ehlers, LB; Love-Osborne, K; Nadeau, KJ; Zeitler, PS, 2009) |
"Non-alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH." | 5.14 | Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. ( Borg, BB; Feld, JJ; Hoofnagle, JH; Kleiner, DE; Liang, TJ; Loomba, R; Lutchman, G; Modi, A; Nagabhyru, P; Ricks, M; Sumner, AE, 2009) |
"No significant differences between treatment with metformin or placebo were observed for changes in liver steatosis, assessed either histologically or by CT, NAS-score, liver transaminases or on markers of insulin resistance or inflammation." | 5.14 | Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. ( Birkeland, K; Bjøro, K; Eggesbø, HB; Haaland, T; Haukeland, JW; Konopski, Z; Løberg, EM; Raschpichler, G; von Volkmann, HL, 2009) |
"In our 6-month prospective study, both low-dose metformin and dietary treatment alone ameliorated liver steatosis and metabolic derangements in patients with NAFLD." | 5.14 | Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. ( Abenavoli, L; Abenavoli, S; Belfiore, A; De Siena, M; Fruci, B; Garinis, GA; Greco, M; Gulletta, E; Mazza, A; Ventura, V, 2010) |
"Previous studies demonstrated that in experimental animals fatty liver is associated with reduced hepatic blood flow and that metformin reverses steatosis, while no data were reported in humans." | 5.11 | Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study. ( Berzigotti, A; Bianchi, G; Magalotti, D; Marchesini, G; Ramilli, S; Zoli, M, 2004) |
"Open-label treatment with metformin for 24 weeks was notable for improvement in liver chemistry, liver fat, insulin sensitivity and quality of life." | 5.11 | A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. ( Deutsch, R; Lavine, JE; Middleton, MS; Schwimmer, JB, 2005) |
"Metformin proved useful in the treatment of nonalcoholic fatty liver disease (NAFLD), but its superiority over nutritional treatment and antioxidants has never been demonstrated." | 5.11 | A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. ( Bugianesi, E; David, E; Gentilcore, E; Manini, R; Marchesini, G; Natale, S; Rizzetto, M; Vanni, E; Villanova, N, 2005) |
"A MEDLINE, Pubmed and Cochrane Review database search using a combination of keywords, which included non-alcoholic fatty liver disease, non-alcoholic hepatic steatosis, NAFLD, NASH, treatment, therapeutics, vitamin E, orlistat and bariatric surgery." | 4.90 | Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. ( Henry, L; Mehta, R; Mishra, A; Reyes, MJ; Younossi, ZM, 2014) |
"Metformin is a widely used and extensively studied insulin sensitising drug for the treatment of women with polycystic ovary syndrome (PCOS), with various actions in tissues responding to insulin that include the liver, skeletal muscle, adipose tissue, the endothelium of blood vessels, and the ovaries." | 4.88 | Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. ( Hodges, P; Randeva, HS; Tan, BK; Weickert, MO, 2012) |
" Metformin, a common therapeutic option for hyperglycemia in type 2 diabetes patients known to partially attenuate fatty liver, reduces the infection of human and hACE2 hepatocytes." | 4.12 | The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes. ( Azkargorta, M; Bravo, M; Delgado, TC; Egia-Mendikute, L; Eguileor Giné, A; Elortza, F; Ereño-Orbea, J; Gil-Pitarch, C; Goikoetxea-Usandizaga, N; González-Recio, I; Jiménez-Barbero, J; Jover, R; Lachiondo-Ortega, S; Lee, SY; Martínez-Chantar, ML; Martínez-Cruz, LA; Mercado-Gómez, M; Nogueiras, R; Palazon, A; Petrov, P; Prevot, V; Prieto-Fernández, E; Rodríguez-Agudo, R; Serrano-Maciá, M; Simón, J; Vila-Vecilla, L, 2022) |
"To examine the effect of metformin treatment during ischemia/reperfusion injury in fatty liver and determine the possible mechanisms." | 3.96 | Metformin Attenuates Ischemia-reperfusion Injury of Fatty Liver in Rats Through Inhibition of the TLR4/NF-κB Axis ( Huang, C; Li, X; Wang, L; Yang, X, 2020) |
"Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders." | 3.91 | Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota. ( Adeshirlarijaney, A; Chassaing, B; Gewirtz, AT; Tran, HQ; Zou, J, 2019) |
"Co-treatment with T317 and metformin inhibited the development of atherosclerosis without activation of lipogenesis, suggesting that combined treatment with T317 and metformin may be a novel approach to inhibition of atherosclerosis." | 3.88 | Functional interplay between liver X receptor and AMP-activated protein kinase α inhibits atherosclerosis in apolipoprotein E-deficient mice - a new anti-atherogenic strategy. ( Chen, Y; Duan, Y; Feng, K; Han, J; Hu, W; Li, L; Li, X; Liu, L; Liu, Y; Ma, C; Miao, RQ; Sun, L; Yang, J; Yang, S; Yang, X; Yu, M; Zhang, W; Zhang, X; Zhu, Y, 2018) |
" We were able to show in vivo that reducing phospho-STAT3-miR-21 levels in C57/BL6 mice liver, by long-term treatment with metformin, protected mice from aging-dependent hepatic vesicular steatosis." | 3.88 | Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. ( Belloni, L; Blandino, G; Di Cocco, S; Guerrieri, F; Levrero, M; Marra, F; Mori, F; Nunn, ADG; Pallocca, M; Pediconi, N; Piconese, S; Pulito, C; Sacconi, A; Salerno, D; Strano, S; Testoni, B; Vivoli, E, 2018) |
"The present study aimed to investigate the effect of metformin on the induction of autophagy in the liver and adipose tissues of a mouse model of obesity." | 3.85 | Metformin ameliorates hepatic steatosis and improves the induction of autophagy in HFD‑induced obese mice. ( Li, M; Sharma, A; Tan, X; Xiao, Y; Yin, C, 2017) |
" This study investigated the effects of scopoletin on hepatic steatosis and inflammation in a high-fat diet fed type 1 diabetic mice by comparison with metformin." | 3.85 | Scopoletin Supplementation Ameliorates Steatosis and Inflammation in Diabetic Mice. ( Cho, HW; Choi, MS; Choi, RY; Ham, JR; Kim, MJ; Lee, HI; Lee, J; Lee, MK; Park, SK; Seo, KI, 2017) |
"In addition to the ascertained efficacy as antidiabetic drug, metformin is increasingly being used as weight-loss agent in obesity, and as insulin sensitizer in nonalcoholic fatty liver disease (NAFLD)." | 3.83 | Metformin increases hepatic leptin receptor and decreases steatosis in mice. ( Cui, Y; Gan, L; Li, J; Tang, X; Wang, X; Xiang, W; Xie, B; Xu, Z, 2016) |
"We investigated the effects of metformin and celecoxib on obesity-induced adipose tissue inflammation, insulin resistance (IR), fatty liver, and high blood pressure in high-fat (HF) fed rats." | 3.83 | Additional effect of metformin and celecoxib against lipid dysregulation and adipose tissue inflammation in high-fat fed rats with insulin resistance and fatty liver. ( Hsieh, PS; Hung, YJ; Lu, CH, 2016) |
"Here, we sought to compare the efficacy of combining exercise and metformin for the treatment of type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) in hyperphagic, obese, type 2 diabetic Otsuka Long-Evans Tokushima Fatty (OLETF) rats." | 3.80 | Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats. ( Booth, FW; Crissey, JM; Fletcher, JA; Ibdah, JA; Kearney, ML; Laughlin, MH; Linden, MA; Meers, GM; Morris, EM; Rector, RS; Sowers, JR; Thyfault, JP, 2014) |
" To better understand the pathophysiology of obesity-associated NAFLD, the present study examined the involvement of liver and adipose tissues in metformin actions on reducing hepatic steatosis and inflammation during obesity." | 3.80 | Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. ( An, X; Botchlett, R; Chen, L; Guo, T; Guo, X; Hu, X; Huo, Y; Li, H; Li, Q; Pei, Y; Qi, T; Woo, SL; Wu, C; Xiao, X; Xu, H; Xu, Y; Zhao, J; Zhao, Y; Zheng, J, 2014) |
"The administration of a HFD induces insulin resistance in the liver sinusoidal endothelium, which is mediated, at least in part, through iNOS upregulation and can be prevented by the administration of metformin." | 3.77 | Insulin resistance and liver microcirculation in a rat model of early NAFLD. ( Abraldes, JG; Bosch, J; García-Pagán, JC; La Mura, V; Pasarín, M; Rodríguez-Vilarrupla, A, 2011) |
"To investigate the potential preventive effects of metformin on non-alcoholic fatty liver disease (NAFLD) and roles of phospholipase A2/lysophosphatidylcholine pathway in hepatocyte lipoapoptosis in a rat NAFLD model induced by high-fat diet." | 3.77 | [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes]. ( Fu, JF; Huang, Y; Liu, LR; Shi, HB, 2011) |
" Moreover, in comparingson of changes in HOMA among the groups, the metformin- treated group showed significantly improved metabolic control and insulin sensitivity (HOMA) at the end of the study." | 3.77 | Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. ( Akcam, M; Boyaci, A; Dundar, BN; Kaya, S; Pirgon, O; Uysal, S, 2011) |
"To report a case of idiosyncratic hepatotoxicity associated with metformin in the treatment of type 2 diabetes with nonalcoholic fatty liver disease (NAFLD)." | 3.76 | Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease. ( Bachyrycz, AM; Cone, CJ; Murata, GH, 2010) |
" We followed the spontaneous evolution of liver steatosis and tested the therapeutic usefulness of metformin and fenofibrate in a model of steatosis, the Zucker diabetic fatty (ZDF) rat." | 3.75 | Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. ( Abdallah, P; Basset, A; Beylot, M; del Carmine, P; Forcheron, F; Haffar, G, 2009) |
"Our aim was to evaluate effects of metformin, rosiglitazone, and diet with exercise in nonalcoholic fatty liver disease." | 3.74 | The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. ( Aksoy, N; Akyüz, F; Beşişik, F; Boztaş, G; Cakaloğlu, Y; Cevikbaş, U; Demir, K; Ibrişim, D; Kaymakoğlu, S; Mungan, Z; Okten, A; Ozdil, S; Poturoğlu, S, 2007) |
"A 2-hour oral glucose tolerance test (OGTT) and a rapid intravenous glucose tolerance test (IVGTT) were performed before treatment was initiated, after treatment with metformin and at the end of 1 year of combination therapy with metformin and rosiglitazone to calculate quantitative insulin sensitivity check index (QUICKI) and acute insulin response (AIR)." | 3.74 | Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. ( Anhalt, H; Bhangoo, A; Collin, GB; Maclaren, N; Marshall, JD; Naggert, JK; Sinha, SK; Ten, S, 2007) |
"To explore the therapeutic effects of metformin on rat fatty livers induced by high fat feeding." | 3.73 | [Study on therapeutic effects of metformin on rat fatty livers induced by high fat feeding]. ( Dong, H; Gao, ZQ; Lu, FE; Wang, KF; Xu, LJ; Zhou, X, 2005) |
"To investigate the effects of metformin on fatty livers in insulin-resistant rats." | 3.73 | [Effects of metformin on fatty liver in insulin-resistant rats]. ( Chen, SQ; Deng, JC; Liu, Q; Sun, H; Tang, L, 2005) |
"To investigate the therapeutic effects of insulin-sensitizing drugs, rosiglitazone and metformin, on nonalcoholic fatty liver disease (NAFLD)." | 3.73 | [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats]. ( Chen, WK; Wang, T; Zhang, DM; Zhang, GY; Zhong, HJ, 2006) |
"To assess whether treatment with insulin-sensitizing agents (ISAs) in combination with ezetimibe and valsartan have greater effect on hepatic fat content and lipid peroxidation compared to monotherapy in the methionine choline-deficient diet (MCDD) rat model of non-alcoholic fatty liver disease (NAFLD)." | 3.73 | Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. ( Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S, 2006) |
"In patients with type 2 diabetes who were inadequately controlled with metformin and sulphonylurea, we compared the glucose-lowering efficacy, cardiometabolic parameters and safety of two drugs, ipragliflozin, a sodium-glucose cotransporter-2 inhibitor, and sitagliptin, a dipeptidyl peptidase-4 inhibitor." | 3.30 | Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study. ( Kang, SM; Lim, S; Sohn, M; Yun, HM, 2023) |
"Metformin-treated girls gained more height per bone-age year and had less visceral and hepatic fat." | 2.87 | Metformin for Rapidly Maturing Girls with Central Adiposity: Less Liver Fat and Slower Bone Maturation. ( de Zegher, F; García Beltrán, C; Ibáñez, L; López-Bermejo, A, 2018) |
"Individuals with type 2 diabetes (n = 44) and glycated hemoglobin ≤ 7." | 2.80 | Effect of vildagliptin on hepatic steatosis. ( Al-Mrabeh, A; Foley, JE; Hollingsworth, KG; Macauley, M; Schweizer, A; Smith, FE; Taylor, R; Thelwall, PE, 2015) |
"Liraglutide treatment was also associated with a significant improvement in glycated hemoglobin (7." | 2.80 | Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. ( Castel, H; Chartrand, G; Chiasson, JL; de Guise, J; Gilbert, G; Julien, AS; Massicotte-Tisluck, K; Olivié, D; Rabasa-Lhoret, R; Soulez, G; Tang, A; Wartelle-Bladou, C, 2015) |
"Pioglitazone was more effective than glibenclamide in improving inflammation and hepatic steatosis indices." | 2.78 | Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. ( D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Perrone, T, 2013) |
"Fetuin A levels were elevated in NAFLD." | 2.77 | Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. ( Aasheim, ET; Aukrust, P; Birkeland, KI; Dahl, TB; Gladhaug, IP; Haaland, T; Halvorsen, B; Haukeland, JW; Johansen, OE; Konopski, Z; Løberg, EM; Wium, C; Yndestad, A, 2012) |
"Metformin treatment was associated with significant decrease in AI during one year treatment in NAFLD patients." | 2.77 | Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? ( Boaz, M; Gavish, D; Matas, Z; Omelchenko, E; Shargorodsky, M, 2012) |
"Patients with treatment-naive type 2 diabetes (N = 16) were treated with insulin and metformin for a 3-month lead-in period, then assigned triple oral therapy (metformin, glyburide, and pioglitazone) or continued treatment with insulin and metformin." | 2.77 | Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. ( Duong, J; Leonard, D; Lingvay, I; Roe, ED; Szczepaniak, LS, 2012) |
"Metformin treatment was associated with significant decrease in PWV and AI in NAFLD patients." | 2.76 | Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. ( Boaz, M; Mashavi, M; Matas, Z; Shargorodsky, M; Sofer, E, 2011) |
" Interventions Daily dosing of 800 IU of vitamin E (58 patients), 1000 mg of metformin (57 patients), or placebo (58 patients) for 96 weeks." | 2.76 | Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. ( Abrams, SH; Brunt, EM; Chalasani, N; Clark, JM; Hoofnagle, JH; Kleiner, DE; Lavine, JE; Molleston, JP; Murray, KF; Robuck, PR; Rosenthal, P; Sanyal, AJ; Scheimann, AO; Schwimmer, JB; Tonascia, J; Ünalp, A; Van Natta, ML, 2011) |
"Insulin resistance is a major feature of type 2 diabetes mellitus, obesity and nonalcoholic fatty liver disease (NAFLD)." | 2.74 | The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. ( Gedik, O; Nar, A, 2009) |
"The increased risk of type 2 diabetes and cardiovascular disease in PCOS is closely associated with BMI." | 2.55 | Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. ( Andersen, M; Glintborg, D, 2017) |
"Metformin is a first-line drug in the treatment of overweight and obese type 2 diabetic patients, offering a selective pathophysiological approach by its effect on insulin resistance." | 2.50 | The therapy of insulin resistance in other diseases besides type 2 diabetes. ( Barbaro, V; Dicembrini, I; Pala, L; Rotella, CM, 2014) |
"Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide." | 2.49 | Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. ( Belfiore, A; Fruci, B; Giuliano, S; Malaguarnera, R; Mazza, A, 2013) |
"Nonalcoholic fatty liver disease (NAFLD) is characterized by the accumulation of triglycerides in hepatocytes in the absence of excessive alcohol intake, ranging in severity from simple steatosis to nonalcoholic steatohepatitis (NASH)." | 2.49 | Pharmacologic therapy for nonalcoholic fatty liver disease in adults. ( Bell, AM; Byrd, JS; Malinowski, SS; Riche, DM; Wofford, MR, 2013) |
"Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disorder worldwide, comprises a spectrum of conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis." | 2.49 | Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. ( Baldelli, E; Carulli, L; George, J; Hebbard, L; Loria, P; Maurantonio, M, 2013) |
"Metformin is an antidiabetic drug used widely in clinical practice." | 2.48 | Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease. ( Barbero-Becerra, VJ; Chavez-Tapia, NC; Mendez-Sanchez, N; Santiago-Hernandez, JJ; Uribe, M; Villegas-Lopez, FA, 2012) |
"Obesity is known to be the most common cause of simple steatosis in the preadolescent and adolescent population with a consequent serious health risk." | 2.47 | [Fatty liver and its clinical management in obese adolescents]. ( Álvarez Ferre, J; González Jiménez, E; Schmidt Río-Valle, J, 2011) |
"Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized cause of liver disease worldwide." | 2.47 | Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic. ( Ismail, MH, 2011) |
"Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world." | 2.47 | Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. ( Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N, 2011) |
"Insulin resistance is a new target in the challenging management of chronic hepatitis C." | 2.46 | Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management. ( del Campo, JA; López, RA; Romero-Gómez, M, 2010) |
"Insulin resistance is nearly universal in NASH and is thought to play an important role in its pathogenesis leading to dysregulated lipid metabolism." | 2.45 | Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. ( Dong, MH; Loomba, R; Stein, LL, 2009) |
"Early stages of fatty liver are clinically silent and include elevation of ALT and GGTP, hyperechogenic liver in USG and/or hepatomegaly." | 2.44 | [Non-alcoholic fatty liver disease--new view]. ( Lawniczak, M; Marlicz, W; Miezyńska-Kurtycz, J; Milkiewicz, P; Raszeja-Wyszomirska, J, 2008) |
"Nonalcoholic steatohepatitis (NASH) is one of the most common liver disorders in North America." | 2.44 | Treatment of fibrosis in nonalcoholic fatty liver disease. ( Anania, FA; Hoteit, MA, 2007) |
"Obesity is not necessary to observe insulin resistance in humans since severe insulin resistance also characterizes patients lacking subcutaneous fat such as those with HAART (highly-active antiretroviral therapy) - associated lipodystrophy." | 2.43 | The fatty liver and insulin resistance. ( Westerbacka, J; Yki-Järvinen, H, 2005) |
"Non-alcoholic steatohepatitis once considered a benign process is now known to lead to progressive fibrosis and cirrhosis." | 2.43 | Review article: Drug therapy for non-alcoholic fatty liver disease. ( Comar, KM; Sterling, RK, 2006) |
"Insulin resistance is an integral part of the underlying pathophysiology in most patients with nonalcoholic fatty liver disease (NAFLD)." | 2.43 | Therapy of NAFLD: insulin sensitizing agents. ( Al-Osaimi, AM; Argo, CK; Caldwell, SH, 2006) |
"Nonalcoholic steatohepatitis (NASH), which is considered the hepatic manifestation of the metabolic syndrome is an increasingly cause of chronic liver disease in Japan." | 2.43 | [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. ( Kawaguchi, K; Korenaga, K; Korenaga, M; Sakaida, I; Uchida, K, 2006) |
"Metformin is a widely used drug in the therapy of patients affected by diabetes mellitus." | 2.43 | Metformin beyond diabetes: new life for an old drug. ( Mannucci, E; Monami, M; Rotella, CM, 2006) |
"Metformin, a biguanide, has been available in the US for the treatment of type 2 diabetes mellitus for nearly 8 years." | 2.42 | Metformin: new understandings, new uses. ( Hundal, RS; Inzucchi, SE, 2003) |
"Metformin therapy was found to eliminate fatty liver disease in this model." | 2.42 | Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach. ( Barkin, JS; Hookman, P, 2003) |
"Dulaglutide is approved in type 2 diabetes as a hypoglycemic agent." | 1.91 | Glp-1 Receptor Agonists Regulate the Progression of Diabetes Mellitus Complicated with Fatty Liver by Down-regulating the Expression of Genes Related to Lipid Metabolism. ( Chen, H; Huang, H; Liu, Y; Zheng, S, 2023) |
"Metformin alone reduced hyperinsulinemia and circulating c-reactive protein, but exacerbated nephropathy." | 1.72 | Rapamycin/metformin co-treatment normalizes insulin sensitivity and reduces complications of metabolic syndrome in type 2 diabetic mice. ( Calcutt, NA; Doty, R; Flurkey, K; Harrison, DE; Koza, RA; Reifsnyder, PC, 2022) |
"Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models." | 1.72 | Sex-specific effects of maternal metformin intervention during glucose-intolerant obese pregnancy on body composition and metabolic health in aged mouse offspring. ( Aiken, CE; Ashmore, TJ; Blackmore, HL; Dearden, L; Fernandez-Twinn, DS; Ozanne, SE; Pantaleão, LC; Pellegrini Pisani, L; Schoonejans, JM; Tadross, JA, 2022) |
"Metformin was treated daily for 14 weeks in a high-fat dieting C57BL/6J mice." | 1.43 | Metformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21. ( Byun, JK; Cho, ML; Choi, JY; Jeong, JH; Jhun, JY; Kim, EK; Kim, JK; Lee, SH; Lee, SY, 2016) |
"From the 479 patients with NAFLD assessed, 302 patients (63%) greater than 18 years old were included." | 1.39 | NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. ( Björnsson, E; Enders, F; Lindor, KD; Suwanwalaikorn, S; Treeprasertsuk, S, 2013) |
"Metformin has recently drawn attention because of its potential antitumor effect." | 1.39 | Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. ( Aoki, K; Atsumi, T; Inoue, H; Ito, Y; Kaji, M; Nagashima, Y; Nakamura, A; Orime, K; Sakamoto, E; Sato, K; Shirakawa, J; Tajima, K; Terauchi, Y; Togashi, Y, 2013) |
"Nonalcoholic fatty liver disease (NAFLD), one of chronic liver diseases, seems to be rising as the obesity epidemic continues." | 1.38 | Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease. ( Chen, J; Chen, L; Huang, L; Lai, H; Liang, X; Liu, J; Ma, L; Pei, H; Peng, A; Ran, Y; Sang, Y; Wei, Y; Xiang, M; Xie, C, 2012) |
"Nonalcoholic fatty liver disease (NAFLD) is strongly associated with insulin resistance." | 1.38 | Proteomic analysis of liver mitochondria of apolipoprotein E knockout mice treated with metformin. ( Korbut, R; Madej, J; Okoń, K; Olszanecki, R; Stachowicz, A; Suski, M, 2012) |
"Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes." | 1.38 | Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. ( Ando, H; Fujimura, A; Hayashi, K; Kaneko, S; Kato, K; Kimura, T; Kita, Y; Kurita, S; Matsuzawa-Nagata, N; Misu, H; Miyamoto, K; Nakanuma, Y; Ni, Y; Ota, T; Otoda, T; Takamura, T; Takeshita, Y; Uno, M; Zen, Y, 2012) |
"non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes are associated with dyslipidaemia, inflammation and oxidative stress." | 1.37 | Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. ( Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R, 2011) |
"There is no known treatment for fatty liver, a ubiquitous cause of chronic liver disease." | 1.31 | Metformin reverses fatty liver disease in obese, leptin-deficient mice. ( Chuckaree, C; Diehl, AM; Kuhajda, F; Lin, HZ; Ronnet, G; Yang, SQ, 2000) |
"There is no established treatment for steatohepatitis in patients who are not alcoholics." | 1.31 | Metformin in non-alcoholic steatohepatitis. ( Bianchi, G; Brizi, M; Marchesini, G; Melchionda, N; Tomassetti, S; Zoli, M, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (2.41) | 18.7374 |
1990's | 1 (0.60) | 18.2507 |
2000's | 57 (34.34) | 29.6817 |
2010's | 95 (57.23) | 24.3611 |
2020's | 9 (5.42) | 2.80 |
Authors | Studies |
---|---|
Ma, L | 1 |
Xie, C | 1 |
Ran, Y | 1 |
Liang, X | 2 |
Huang, L | 1 |
Pei, H | 1 |
Chen, J | 1 |
Liu, J | 3 |
Sang, Y | 1 |
Lai, H | 1 |
Peng, A | 1 |
Xiang, M | 1 |
Wei, Y | 1 |
Chen, L | 6 |
Mercado-Gómez, M | 1 |
Prieto-Fernández, E | 1 |
Goikoetxea-Usandizaga, N | 1 |
Vila-Vecilla, L | 1 |
Azkargorta, M | 1 |
Bravo, M | 1 |
Serrano-Maciá, M | 1 |
Egia-Mendikute, L | 1 |
Rodríguez-Agudo, R | 1 |
Lachiondo-Ortega, S | 1 |
Lee, SY | 2 |
Eguileor Giné, A | 1 |
Gil-Pitarch, C | 1 |
González-Recio, I | 1 |
Simón, J | 1 |
Petrov, P | 1 |
Jover, R | 1 |
Martínez-Cruz, LA | 1 |
Ereño-Orbea, J | 1 |
Delgado, TC | 1 |
Elortza, F | 1 |
Jiménez-Barbero, J | 1 |
Nogueiras, R | 1 |
Prevot, V | 1 |
Palazon, A | 1 |
Martínez-Chantar, ML | 1 |
Reifsnyder, PC | 1 |
Flurkey, K | 1 |
Doty, R | 1 |
Calcutt, NA | 1 |
Koza, RA | 1 |
Harrison, DE | 1 |
Schoonejans, JM | 1 |
Blackmore, HL | 1 |
Ashmore, TJ | 1 |
Pantaleão, LC | 1 |
Pellegrini Pisani, L | 1 |
Dearden, L | 1 |
Tadross, JA | 1 |
Aiken, CE | 1 |
Fernandez-Twinn, DS | 1 |
Ozanne, SE | 1 |
Kang, SM | 2 |
Yun, HM | 1 |
Sohn, M | 1 |
Lim, S | 2 |
Zheng, S | 1 |
Huang, H | 1 |
Chen, H | 1 |
Liu, Y | 2 |
Adeshirlarijaney, A | 1 |
Zou, J | 1 |
Tran, HQ | 1 |
Chassaing, B | 1 |
Gewirtz, AT | 1 |
Li, X | 2 |
Wang, L | 1 |
Yang, X | 3 |
Huang, C | 1 |
Liu, Q | 2 |
Li, L | 3 |
Gao, L | 1 |
Li, C | 1 |
Huan, Y | 1 |
Lei, L | 1 |
Cao, H | 1 |
Gao, A | 1 |
Liu, S | 1 |
Shen, Z | 1 |
de Zegher, F | 2 |
Díaz, M | 1 |
Villarroya, J | 1 |
Cairó, M | 1 |
López-Bermejo, A | 2 |
Villarroya, F | 1 |
Ibáñez, L | 2 |
Zhang, X | 2 |
Zhuang, Y | 1 |
Qin, T | 1 |
Chang, M | 1 |
Ji, X | 1 |
Wang, N | 1 |
Zhang, Z | 1 |
Zhou, H | 1 |
Wang, Q | 1 |
Li, JZ | 1 |
Li, M | 2 |
Sharma, A | 1 |
Yin, C | 1 |
Tan, X | 1 |
Xiao, Y | 1 |
Kosi-Trebotic, L | 1 |
Thomas, A | 1 |
Harreiter, J | 1 |
Chmelik, M | 1 |
Trattnig, S | 1 |
Kautzky-Willer, A | 1 |
Glintborg, D | 1 |
Andersen, M | 1 |
Choi, RY | 1 |
Ham, JR | 1 |
Lee, HI | 1 |
Cho, HW | 1 |
Choi, MS | 1 |
Park, SK | 1 |
Lee, J | 1 |
Kim, MJ | 1 |
Seo, KI | 1 |
Lee, MK | 1 |
García Beltrán, C | 1 |
Boudaba, N | 1 |
Marion, A | 1 |
Huet, C | 1 |
Pierre, R | 1 |
Viollet, B | 1 |
Foretz, M | 1 |
Ma, C | 1 |
Zhang, W | 1 |
Liu, L | 1 |
Feng, K | 1 |
Yang, S | 1 |
Sun, L | 1 |
Yu, M | 1 |
Yang, J | 1 |
Hu, W | 1 |
Miao, RQ | 1 |
Zhu, Y | 1 |
Han, J | 1 |
Chen, Y | 1 |
Duan, Y | 1 |
Chang, HH | 1 |
Moro, A | 1 |
Chou, CEN | 1 |
Dawson, DW | 1 |
French, S | 1 |
Schmidt, AI | 1 |
Sinnett-Smith, J | 1 |
Hao, F | 1 |
Hines, OJ | 1 |
Eibl, G | 1 |
Rozengurt, E | 1 |
Zabielski, P | 1 |
Hady, HR | 1 |
Chacinska, M | 1 |
Roszczyc, K | 1 |
Gorski, J | 1 |
Blachnio-Zabielska, AU | 1 |
Belloni, L | 1 |
Di Cocco, S | 1 |
Guerrieri, F | 1 |
Nunn, ADG | 1 |
Piconese, S | 1 |
Salerno, D | 1 |
Testoni, B | 1 |
Pulito, C | 1 |
Mori, F | 1 |
Pallocca, M | 1 |
Sacconi, A | 1 |
Vivoli, E | 1 |
Marra, F | 1 |
Strano, S | 1 |
Blandino, G | 1 |
Levrero, M | 1 |
Pediconi, N | 1 |
Zhang, C | 1 |
Hu, J | 1 |
Sheng, L | 1 |
Yuan, M | 1 |
Wu, Y | 1 |
Zheng, G | 1 |
Qiu, Z | 1 |
Treeprasertsuk, S | 1 |
Björnsson, E | 1 |
Enders, F | 1 |
Suwanwalaikorn, S | 1 |
Lindor, KD | 1 |
Maffioli, P | 1 |
Fogari, E | 1 |
D'Angelo, A | 1 |
Perrone, T | 1 |
Derosa, G | 1 |
Tajima, K | 1 |
Nakamura, A | 1 |
Shirakawa, J | 1 |
Togashi, Y | 1 |
Orime, K | 1 |
Sato, K | 1 |
Inoue, H | 1 |
Kaji, M | 1 |
Sakamoto, E | 1 |
Ito, Y | 1 |
Aoki, K | 1 |
Nagashima, Y | 1 |
Atsumi, T | 1 |
Terauchi, Y | 1 |
Younossi, ZM | 1 |
Reyes, MJ | 1 |
Mishra, A | 1 |
Mehta, R | 1 |
Henry, L | 1 |
Liu, F | 1 |
Wang, C | 2 |
Zhang, L | 1 |
Xu, Y | 3 |
Jang, L | 1 |
Gu, Y | 1 |
Cao, X | 1 |
Zhao, X | 1 |
Ye, J | 1 |
Li, Q | 2 |
Fruci, B | 3 |
Giuliano, S | 2 |
Mazza, A | 3 |
Malaguarnera, R | 2 |
Belfiore, A | 3 |
Mazzella, N | 1 |
Ricciardi, LM | 1 |
Mazzotti, A | 1 |
Marchesini, G | 7 |
Linden, MA | 1 |
Fletcher, JA | 1 |
Morris, EM | 1 |
Meers, GM | 1 |
Kearney, ML | 1 |
Crissey, JM | 1 |
Laughlin, MH | 1 |
Booth, FW | 1 |
Sowers, JR | 1 |
Ibdah, JA | 1 |
Thyfault, JP | 1 |
Rector, RS | 1 |
Fan, H | 1 |
Pan, Q | 1 |
Hong, ES | 1 |
Kim, EK | 2 |
Khang, AR | 1 |
Choi, SH | 1 |
Park, KS | 1 |
Jang, HC | 1 |
Woo, SL | 1 |
Xu, H | 1 |
Li, H | 1 |
Zhao, Y | 1 |
Hu, X | 1 |
Zhao, J | 1 |
Guo, X | 1 |
Guo, T | 1 |
Botchlett, R | 1 |
Qi, T | 1 |
Pei, Y | 1 |
Zheng, J | 1 |
An, X | 1 |
Xiao, X | 1 |
Huo, Y | 1 |
Wu, C | 1 |
Shu, Y | 1 |
Chen, EC | 1 |
Yee, SW | 2 |
Zur, AA | 1 |
Li, S | 1 |
Xu, L | 1 |
Keshari, KR | 1 |
Lin, MJ | 1 |
Chien, HC | 1 |
Zhang, Y | 2 |
Morrissey, KM | 1 |
Ostrem, J | 1 |
Younger, NS | 1 |
Kurhanewicz, J | 1 |
Shokat, KM | 1 |
Ashrafi, K | 1 |
Giacomini, KM | 2 |
Yang, L | 1 |
Song, MQ | 1 |
Zhang, QL | 1 |
Shou, L | 1 |
Zang, SF | 1 |
Yang, YL | 1 |
Pala, L | 1 |
Barbaro, V | 1 |
Dicembrini, I | 1 |
Rotella, CM | 2 |
Song, YM | 2 |
Lee, YH | 2 |
Kim, JW | 1 |
Ham, DS | 1 |
Kang, ES | 2 |
Cha, BS | 2 |
Lee, HC | 1 |
Lee, BW | 2 |
Macauley, M | 1 |
Hollingsworth, KG | 2 |
Smith, FE | 1 |
Thelwall, PE | 1 |
Al-Mrabeh, A | 1 |
Schweizer, A | 1 |
Foley, JE | 1 |
Taylor, R | 2 |
Tang, A | 1 |
Rabasa-Lhoret, R | 1 |
Castel, H | 1 |
Wartelle-Bladou, C | 1 |
Gilbert, G | 1 |
Massicotte-Tisluck, K | 1 |
Chartrand, G | 1 |
Olivié, D | 1 |
Julien, AS | 1 |
de Guise, J | 1 |
Soulez, G | 1 |
Chiasson, JL | 1 |
Cassidy, S | 1 |
Thoma, C | 1 |
Hallsworth, K | 1 |
Parikh, J | 1 |
Jakovljevic, DG | 1 |
Trenell, MI | 1 |
Wang, FZ | 1 |
Xie, ZS | 1 |
Xing, L | 1 |
Zhang, BF | 1 |
Zhang, JL | 1 |
Cui, PF | 1 |
Qiao, JB | 1 |
Shi, K | 1 |
Cho, CS | 1 |
Cho, MH | 1 |
Xu, X | 1 |
Li, P | 1 |
Jiang, HL | 1 |
Kutbay, NO | 1 |
Yurekli, BS | 1 |
Onay, H | 1 |
Altay, CT | 1 |
Atik, T | 1 |
Hekimsoy, Z | 1 |
Saygili, F | 1 |
Akinci, B | 1 |
Lee, WK | 1 |
García-Heredia, A | 1 |
Riera-Borrull, M | 1 |
Fort-Gallifa, I | 1 |
Luciano-Mateo, F | 1 |
Cabré, N | 1 |
Hernández-Aguilera, A | 1 |
Joven, J | 1 |
Camps, J | 1 |
Meng, X | 1 |
Guo, J | 1 |
Fang, W | 1 |
Dou, L | 1 |
Huang, X | 1 |
Zhou, S | 1 |
Man, Y | 1 |
Tang, W | 1 |
Yu, L | 1 |
Li, J | 2 |
Lee, SH | 1 |
Jhun, JY | 1 |
Byun, JK | 1 |
Jeong, JH | 1 |
Kim, JK | 1 |
Choi, JY | 1 |
Cho, ML | 1 |
Tang, X | 1 |
Xiang, W | 1 |
Cui, Y | 1 |
Xie, B | 1 |
Wang, X | 1 |
Xu, Z | 1 |
Gan, L | 1 |
Lu, CH | 1 |
Hung, YJ | 1 |
Hsieh, PS | 1 |
Mubeen, S | 1 |
Amjad, Z | 1 |
Memon, FM | 1 |
Ashraf, SU | 1 |
Takemori, H | 1 |
Fu, J | 1 |
Xu, M | 1 |
Xiong, L | 1 |
Li, N | 2 |
Wen, X | 1 |
Nobili, V | 3 |
Manco, M | 1 |
Ciampalini, P | 1 |
Alisi, A | 2 |
Devito, R | 1 |
Bugianesi, E | 3 |
Marcellini, M | 1 |
Raszeja-Wyszomirska, J | 1 |
Lawniczak, M | 1 |
Marlicz, W | 1 |
Miezyńska-Kurtycz, J | 1 |
Milkiewicz, P | 1 |
Nadeau, KJ | 1 |
Ehlers, LB | 1 |
Zeitler, PS | 1 |
Love-Osborne, K | 1 |
Nar, A | 1 |
Gedik, O | 1 |
Loomba, R | 2 |
Lutchman, G | 1 |
Kleiner, DE | 2 |
Ricks, M | 1 |
Feld, JJ | 1 |
Borg, BB | 1 |
Modi, A | 1 |
Nagabhyru, P | 1 |
Sumner, AE | 1 |
Liang, TJ | 1 |
Hoofnagle, JH | 2 |
Kashi, MR | 1 |
Torres, DM | 2 |
Harrison, SA | 2 |
Patton, HM | 1 |
Lavine, JE | 8 |
Van Natta, ML | 2 |
Schwimmer, JB | 6 |
Kleiner, D | 1 |
Molleston, J | 1 |
Vuppalanchi, R | 1 |
Chalasani, N | 5 |
Raso, GM | 1 |
Esposito, E | 1 |
Iacono, A | 1 |
Pacilio, M | 1 |
Cuzzocrea, S | 1 |
Canani, RB | 1 |
Calignano, A | 1 |
Meli, R | 1 |
Fischer, R | 1 |
Shneider, B | 1 |
Mascitelli, L | 1 |
Pezzetta, F | 1 |
Goldstein, MR | 1 |
Socha, P | 2 |
Horvath, A | 1 |
Vajro, P | 1 |
Dziechciarz, P | 1 |
Dhawan, A | 1 |
Szajewska, H | 1 |
Forcheron, F | 1 |
Abdallah, P | 1 |
Basset, A | 1 |
del Carmine, P | 1 |
Haffar, G | 1 |
Beylot, M | 1 |
Omer, Z | 1 |
Cetinkalp, S | 1 |
Akyildiz, M | 1 |
Yilmaz, F | 1 |
Batur, Y | 1 |
Yilmaz, C | 1 |
Akarca, U | 1 |
Molleston, JP | 2 |
Scheimann, AO | 2 |
Murray, KF | 2 |
Abrams, SH | 2 |
Rosenthal, P | 2 |
Sanyal, AJ | 3 |
Robuck, PR | 2 |
Brunt, EM | 3 |
Unalp, A | 2 |
Tonascia, J | 2 |
Haukeland, JW | 2 |
Konopski, Z | 2 |
Eggesbø, HB | 1 |
von Volkmann, HL | 1 |
Raschpichler, G | 1 |
Bjøro, K | 1 |
Haaland, T | 2 |
Løberg, EM | 2 |
Birkeland, K | 1 |
Stein, LL | 1 |
Dong, MH | 1 |
Jin, X | 1 |
Yu, CH | 1 |
Chen, SH | 1 |
Li, WP | 1 |
Li, YM | 1 |
Garinis, GA | 2 |
De Siena, M | 1 |
Abenavoli, S | 1 |
Gulletta, E | 1 |
Ventura, V | 1 |
Greco, M | 1 |
Abenavoli, L | 3 |
Krakoff, J | 1 |
Clark, JM | 2 |
Crandall, JP | 1 |
Wilson, C | 1 |
Molitch, ME | 1 |
Brancati, FL | 1 |
Edelstein, SL | 1 |
Knowler, WC | 1 |
del Campo, JA | 1 |
López, RA | 1 |
Romero-Gómez, M | 1 |
Tharayil, V | 1 |
Roberts, LR | 1 |
Cone, CJ | 1 |
Bachyrycz, AM | 1 |
Murata, GH | 1 |
Brouwers, MC | 1 |
de Graaf, J | 1 |
van Greevenbroek, MM | 1 |
Schaper, N | 1 |
Stehouwer, CD | 1 |
Stalenhoef, AF | 1 |
Rakoski, MO | 1 |
Singal, AG | 1 |
Rogers, MA | 1 |
Conjeevaram, H | 1 |
Ratziu, V | 1 |
Caldwell, S | 1 |
Neuschwander-Tetri, BA | 1 |
González Jiménez, E | 1 |
Schmidt Río-Valle, J | 1 |
Álvarez Ferre, J | 1 |
Matafome, P | 1 |
Louro, T | 1 |
Rodrigues, L | 1 |
Crisóstomo, J | 1 |
Nunes, E | 1 |
Amaral, C | 1 |
Monteiro, P | 1 |
Cipriano, A | 1 |
Seiça, R | 1 |
Pasarín, M | 1 |
Abraldes, JG | 1 |
Rodríguez-Vilarrupla, A | 1 |
La Mura, V | 1 |
García-Pagán, JC | 1 |
Bosch, J | 1 |
Brufani, C | 1 |
Fintini, D | 1 |
Patera, PI | 1 |
Cappa, M | 1 |
Brufani, M | 1 |
Sofer, E | 1 |
Boaz, M | 2 |
Matas, Z | 2 |
Mashavi, M | 1 |
Shargorodsky, M | 2 |
Ismail, MH | 1 |
Huang, Y | 1 |
Fu, JF | 1 |
Shi, HB | 1 |
Liu, LR | 1 |
Li, Y | 1 |
Xu, S | 1 |
Mihaylova, MM | 1 |
Zheng, B | 1 |
Hou, X | 1 |
Jiang, B | 1 |
Park, O | 1 |
Luo, Z | 1 |
Lefai, E | 1 |
Shyy, JY | 1 |
Gao, B | 1 |
Wierzbicki, M | 1 |
Verbeuren, TJ | 1 |
Shaw, RJ | 1 |
Cohen, RA | 1 |
Zang, M | 1 |
Sharif, A | 1 |
Pacifico, L | 1 |
Anania, C | 1 |
Martino, F | 1 |
Poggiogalle, E | 1 |
Chiarelli, F | 1 |
Arca, M | 1 |
Chiesa, C | 1 |
Jones, FJ | 1 |
Shaw, JC | 1 |
Williams, CD | 1 |
Ward, JA | 1 |
Sookoian, S | 1 |
Pirola, CJ | 1 |
Retnakaran, R | 1 |
Ye, C | 1 |
Hanley, AJ | 1 |
Harris, SB | 1 |
Zinman, B | 1 |
Corey, KE | 1 |
Samson, SL | 1 |
Sathyanarayana, P | 1 |
Jogi, M | 1 |
Gonzalez, EV | 1 |
Gutierrez, A | 1 |
Krishnamurthy, R | 1 |
Muthupillai, R | 1 |
Chan, L | 1 |
Bajaj, M | 1 |
Shyangdan, D | 1 |
Clar, C | 1 |
Ghouri, N | 1 |
Henderson, R | 1 |
Gurung, T | 1 |
Preiss, D | 1 |
Sattar, N | 1 |
Fraser, A | 1 |
Waugh, N | 1 |
Andrews, DB | 1 |
Dahl, TB | 1 |
Yndestad, A | 1 |
Gladhaug, IP | 1 |
Wium, C | 1 |
Aasheim, ET | 1 |
Johansen, OE | 1 |
Aukrust, P | 1 |
Halvorsen, B | 1 |
Birkeland, KI | 1 |
Weickert, MO | 1 |
Hodges, P | 1 |
Tan, BK | 1 |
Randeva, HS | 1 |
Younossi, Z | 1 |
Diehl, AM | 2 |
Cusi, K | 1 |
Charlton, M | 1 |
Barbero-Becerra, VJ | 1 |
Santiago-Hernandez, JJ | 1 |
Villegas-Lopez, FA | 1 |
Mendez-Sanchez, N | 1 |
Uribe, M | 2 |
Chavez-Tapia, NC | 2 |
Janczyk, W | 1 |
Spruss, A | 1 |
Kanuri, G | 1 |
Stahl, C | 1 |
Bischoff, SC | 1 |
Bergheim, I | 1 |
Akcam, M | 1 |
Boyaci, A | 1 |
Pirgon, O | 1 |
Kaya, S | 1 |
Uysal, S | 1 |
Dundar, BN | 1 |
Omelchenko, E | 1 |
Gavish, D | 1 |
Bozzetto, L | 1 |
Prinster, A | 1 |
Annuzzi, G | 1 |
Costagliola, L | 1 |
Mangione, A | 1 |
Vitelli, A | 1 |
Mazzarella, R | 1 |
Longobardo, M | 1 |
Mancini, M | 1 |
Vigorito, C | 1 |
Riccardi, G | 1 |
Rivellese, AA | 1 |
Lingvay, I | 1 |
Roe, ED | 1 |
Duong, J | 1 |
Leonard, D | 1 |
Szczepaniak, LS | 1 |
Stachowicz, A | 1 |
Suski, M | 1 |
Olszanecki, R | 1 |
Madej, J | 1 |
Okoń, K | 1 |
Korbut, R | 1 |
Kita, Y | 1 |
Takamura, T | 1 |
Misu, H | 1 |
Ota, T | 1 |
Kurita, S | 1 |
Takeshita, Y | 1 |
Uno, M | 1 |
Matsuzawa-Nagata, N | 1 |
Kato, K | 1 |
Ando, H | 1 |
Fujimura, A | 1 |
Hayashi, K | 1 |
Kimura, T | 1 |
Ni, Y | 1 |
Otoda, T | 1 |
Miyamoto, K | 1 |
Zen, Y | 1 |
Nakanuma, Y | 1 |
Kaneko, S | 1 |
Su, X | 1 |
Gi, YJ | 1 |
Chakravarti, D | 1 |
Chan, IL | 1 |
Zhang, A | 1 |
Xia, X | 1 |
Tsai, KY | 1 |
Flores, ER | 1 |
Lanaspa, MA | 1 |
Cicerchi, C | 1 |
Garcia, G | 1 |
Roncal-Jimenez, CA | 1 |
Rivard, CJ | 1 |
Hunter, B | 1 |
Andrés-Hernando, A | 1 |
Ishimoto, T | 1 |
Sánchez-Lozada, LG | 1 |
Thomas, J | 1 |
Hodges, RS | 1 |
Mant, CT | 1 |
Johnson, RJ | 1 |
Resuli, B | 1 |
Demiraj, V | 1 |
Babameto, A | 1 |
Sema, K | 1 |
Malaj, V | 1 |
Panahi, Y | 1 |
Ghamarchehreh, ME | 1 |
Beiraghdar, F | 1 |
Zare, R | 1 |
Jalalian, HR | 1 |
Sahebkar, A | 1 |
Chen, YM | 1 |
Liao, YJ | 1 |
Malinowski, SS | 1 |
Byrd, JS | 1 |
Bell, AM | 1 |
Wofford, MR | 1 |
Riche, DM | 1 |
Carulli, L | 1 |
Maurantonio, M | 1 |
Hebbard, L | 1 |
Baldelli, E | 1 |
Loria, P | 1 |
George, J | 1 |
Hookman, P | 2 |
Barkin, JS | 2 |
Hundal, RS | 1 |
Inzucchi, SE | 1 |
Kadayifçi, A | 2 |
Magalotti, D | 1 |
Ramilli, S | 1 |
Berzigotti, A | 1 |
Bianchi, G | 2 |
Zoli, M | 2 |
Marzocchi, R | 1 |
Villanova, N | 2 |
Gao, ZQ | 1 |
Lu, FE | 1 |
Dong, H | 1 |
Xu, LJ | 1 |
Wang, KF | 1 |
Zhou, X | 1 |
Shen, W | 1 |
Middleton, MS | 1 |
Deutsch, R | 1 |
Gentilcore, E | 1 |
Manini, R | 2 |
Natale, S | 2 |
Vanni, E | 1 |
David, E | 1 |
Rizzetto, M | 1 |
Yki-Järvinen, H | 1 |
Westerbacka, J | 1 |
Moreno Sánchez, D | 1 |
Anania, FA | 2 |
Parekh, S | 1 |
Shaukat, A | 1 |
Agostini, F | 1 |
Kluwe, J | 1 |
Lohse, AW | 1 |
Chen, SQ | 1 |
Sun, H | 1 |
Tang, L | 1 |
Deng, JC | 1 |
Comar, KM | 1 |
Sterling, RK | 1 |
Caldwell, SH | 1 |
Argo, CK | 1 |
Al-Osaimi, AM | 1 |
Siebler, J | 1 |
Galle, PR | 1 |
Korenaga, M | 1 |
Kawaguchi, K | 1 |
Korenaga, K | 1 |
Uchida, K | 1 |
Sakaida, I | 1 |
Merriman, RB | 1 |
Zhang, DM | 1 |
Zhang, GY | 1 |
Wang, T | 1 |
Zhong, HJ | 1 |
Chen, WK | 1 |
Assy, N | 1 |
Grozovski, M | 1 |
Bersudsky, I | 1 |
Szvalb, S | 1 |
Hussein, O | 1 |
Tushuizen, ME | 1 |
Bunck, MC | 1 |
Pouwels, PJ | 1 |
van Waesberghe, JH | 1 |
Diamant, M | 1 |
Heine, RJ | 1 |
Hoppin, AG | 1 |
Katz, ES | 1 |
Kaplan, LM | 1 |
Lauwers, GY | 1 |
Barrientos-Gutierrez, T | 1 |
Tellez-Avila, FI | 1 |
Sanchez-Avila, F | 1 |
Montano-Reyes, MA | 1 |
Angelico, F | 1 |
Burattin, M | 1 |
Alessandri, C | 1 |
Del Ben, M | 1 |
Lirussi, F | 1 |
Hoteit, MA | 1 |
Schroeder-Gloeckler, JM | 1 |
Rahman, SM | 1 |
Janssen, RC | 1 |
Qiao, L | 1 |
Shao, J | 1 |
Roper, M | 1 |
Fischer, SJ | 1 |
Lowe, E | 1 |
Orlicky, DJ | 1 |
McManaman, JL | 1 |
Palmer, C | 1 |
Gitomer, WL | 1 |
Huang, W | 1 |
O'Doherty, RM | 1 |
Becker, TC | 1 |
Klemm, DJ | 1 |
Jensen, DR | 1 |
Pulawa, LK | 1 |
Eckel, RH | 1 |
Friedman, JE | 1 |
Akyüz, F | 1 |
Demir, K | 1 |
Ozdil, S | 1 |
Aksoy, N | 1 |
Poturoğlu, S | 1 |
Ibrişim, D | 1 |
Kaymakoğlu, S | 1 |
Beşişik, F | 1 |
Boztaş, G | 1 |
Cakaloğlu, Y | 1 |
Mungan, Z | 1 |
Cevikbaş, U | 1 |
Okten, A | 1 |
Bueverov, AO | 1 |
Bogomolov, PO | 1 |
Maevskaia, MV | 1 |
Khashab, M | 1 |
Sinha, SK | 1 |
Bhangoo, A | 1 |
Anhalt, H | 1 |
Maclaren, N | 1 |
Marshall, JD | 1 |
Collin, GB | 1 |
Naggert, JK | 1 |
Ten, S | 1 |
Monami, M | 1 |
Mannucci, E | 1 |
Targher, G | 1 |
Lippi, G | 1 |
Moghetti, P | 1 |
Idilman, R | 1 |
Mizrak, D | 1 |
Corapcioglu, D | 1 |
Bektas, M | 1 |
Doganay, B | 1 |
Sayki, M | 1 |
Coban, S | 1 |
Erden, E | 1 |
Soykan, I | 1 |
Emral, R | 1 |
Uysal, AR | 1 |
Ozden, A | 1 |
Krentz, AJ | 1 |
Lin, HZ | 1 |
Yang, SQ | 1 |
Chuckaree, C | 1 |
Kuhajda, F | 1 |
Ronnet, G | 1 |
Brizi, M | 1 |
Tomassetti, S | 1 |
Melchionda, N | 1 |
Urso, R | 1 |
Visco-Comandini, U | 1 |
Bischoff, A | 1 |
Marquie, G | 3 |
Agid, R | 2 |
Haese, E | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Omics-based Predictors of NAFLD/Potential NASH: A New Era Towards Valid and Reliable Non-invasive Diagnosis and Personalized Therapy[NCT05301231] | 450 participants (Anticipated) | Observational [Patient Registry] | 2022-08-01 | Not yet recruiting | |||
A Single-center,Double-blind,Randomised,Placebo-controlled,Parallel-group Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin on Insulin Sensitivity and Its Underlying Mechanism in Patients With T2DM Treated With Metformin[NCT01356381] | Phase 4 | 43 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
Randomized Trial of Liraglutide and Insulin Therapy on Hepatic Steatosis as Measured by MRI and MRS in Metformin-treated Patients With Type 2 Diabetes: an Open Pilot Study[NCT01399645] | Phase 2 | 35 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance[NCT02045290] | Phase 3 | 37 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
Improving Insulin Resistance to Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study[NCT02457286] | Phase 1 | 0 participants (Actual) | Interventional | 2015-06-30 | Withdrawn (stopped due to patients do not want to participate) | ||
A Pilot Study: Metformin as an Inflammatory Modulating Therapy in Older Adults Without Diabetes[NCT03772964] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2019-01-22 | Completed | ||
Treatment of Nonalcoholic Steatohepatitis With Metformin[NCT00063232] | Phase 2 | 28 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571] | 1,080 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)[NCT00063635] | Phase 3 | 173 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
Double Blind, Randomized, Placebo Controlled Trial With Metformin in Non-Alcoholic Fatty Liver Disease (NAFLD)[NCT00303537] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2004-11-30 | Active, not recruiting | ||
[NCT01084486] | Phase 1/Phase 2 | 0 participants | Interventional | Completed | |||
Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus[NCT01432405] | Phase 4 | 24 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2019-01-09 | Completed | ||
Influence of Hepatic Inflammation and Hepatocellular Apoptosis on Physical Performance and Training Effect in Patients With Non - Alcoholic Steatohepatitis[NCT02526732] | 44 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
The Effects of Type of Exercise on Hepatic Fat Content and Metabolic Profiles in Non-alcoholic Fatty Liver Disease: A Randomized Trial[NCT02679417] | 38 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
A Single Center, Non-randomized Study to Evaluate the Safety and Efficacy of Left Gastric Artery Embolization, to Promote Short-term Weight Loss in Obese Patients With Nonalcoholic Steatohepatitis (NASH) and Thereby Improve NASH[NCT02933554] | 8 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | |||
Non-invasive Evaluation of Liver Fibrosis, Steatosis, and Nonalcoholic Steatohepatitis in Biopsy-Proven NAFLD Patients[NCT03725631] | 150 participants (Anticipated) | Interventional | 2016-09-01 | Recruiting | |||
Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial[NCT03198572] | Phase 4 | 120 participants (Anticipated) | Interventional | 2017-08-16 | Recruiting | ||
Comparative Clinical Study to Evaluate the Possible Beneficial Effect of Empagliflozin Versus Pioglitazone on Non-diabetic Patients With Non-Alcoholic Steatohepatitis[NCT05605158] | Phase 3 | 56 participants (Anticipated) | Interventional | 2022-11-30 | Not yet recruiting | ||
An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)[NCT02653300] | Phase 2 | 10 participants (Actual) | Interventional | 2018-09-20 | Completed | ||
Assessment of Chronic Kidney Disease in Non Alcoholic Fatty Liver Disease(NAFLD) Patients[NCT04779905] | 62 participants (Actual) | Observational | 2021-02-28 | Completed | |||
Development of Non-invasive Magnetic Resonance Imaging Diagnostic Method for Nonalcoholic Steatohepatitis(NASH)[NCT03375008] | 47 participants (Actual) | Interventional | 2016-09-08 | Completed | |||
A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis[NCT03061721] | Phase 2 | 106 participants (Actual) | Interventional | 2017-04-06 | Completed | ||
A Double-Blind, Randomized, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)[NCT04618744] | Phase 2 | 33 participants (Actual) | Interventional | 2020-11-24 | Completed | ||
Combined Nutritional and Exercise Strategies to Reduce Liver Fat Content in Patients With Type 2 Diabetes[NCT01025856] | 45 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382] | Phase 3 | 60 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly[NCT04841668] | 136 participants (Anticipated) | Observational | 2021-04-10 | Recruiting | |||
A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
Lifestyle Intervention and Antioxidants in Children With Nonalcoholic Fatty Liver Disease: A Randomized, Controlled Trial[NCT00655018] | Phase 2/Phase 3 | 90 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)[NCT00845845] | Phase 2 | 12 participants (Actual) | Interventional | 2006-03-31 | Terminated (stopped due to Terminated due to low enrollment.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
Intervention | percentage of change (Mean) |
---|---|
Metformin | -0 |
Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
Intervention | percentile (Mean) |
---|---|
Metformin | -1 |
Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
Intervention | insulin per kg (Mean) |
---|---|
Metformin | -0.1 |
Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
Intervention | centimeters (Mean) |
---|---|
Metformin | -0 |
Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
Intervention | mm Hg (Mean) | |
---|---|---|
Change in Systolic | Change in Diastolic | |
Metformin | 0 | 0 |
Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
Intervention | percentage (Mean) | |
---|---|---|
HbA1c | Change from Baseline to 26 Weeks | |
Metformin | 9.0 | 0.2 |
Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
Intervention | percentage of participants (Number) | ||
---|---|---|---|
HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
Metformin | 19 | 44 | 3 |
Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
Intervention | mg/dL (Mean) | ||||
---|---|---|---|---|---|
Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
Metformin | -6 | -0 | -0 | 4 | -5 |
Oral Placebo | 2 | 1 | -1 | 6 | 3 |
Grip strength over time. (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)
Intervention | mmHg (Mean) | ||
---|---|---|---|
0 days | 90 days, compared to 0 days | 120 days, compared to 0 days | |
1000mg Exposure | 28.9 | -0.4 | 1.1 |
1500mg Exposure | 25.7 | -.2 | .3 |
500mg Exposure | 28.2 | -5.3 | .1 |
Placebo | 25.7 | -.3 | -.6 |
The SPPB is a group of measures that combines the results of the gait speed, chair stand and balance tests. The minimum is zero (worse performance) and the maximum is 12 (best performance). (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)
Intervention | Units on a scale (Mean) | ||
---|---|---|---|
0d | 90d, change from 0d | 120d, change from 0d | |
1000mg Exposure | 10.8 | 0.4 | 0.2 |
1500mg Exposure | 11.1 | 0.4 | 0.3 |
500mg Exposure | 11.2 | -0.3 | 0 |
Placebo | 10.6 | 1.0 | 0.5 |
Aggregometry area under the curve with the Y-axis being % aggregometry and the X-axis time in minutes. (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)
Intervention | arbitrary units*mins (Mean) | ||||
---|---|---|---|---|---|
0 days | 30 day change from day 0 | 60 days change from day 0 | 90 days change from day 0 | 120 days change from day 0 | |
1000mg Exposure | 67 | 8.9 | -23.5 | 2.4 | 1.0 |
1500mg Exposure | 196 | -166.7 | -139.8 | -222.5 | -196.7 |
500mg Exposure | 56.3 | -34.7 | -28.3 | 1.6 | -49.2 |
Placebo | 83.3 | -29.6 | -49.4 | -66.6 | -47.6 |
"Bacterial communities using 16S rRNA sequencing in relationship to metformin dosing over time. Species richness or diversity in the sample is measured by Choa1 metric. Chao1 is an estimate of how many species are present in an ecosystem. In general, having more species is considered to be healthier and these values typically range from 100-200 for fecal samples. The Chao1 index over numerous samples across time are explored to understand treatment effects." (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)
Intervention | Index (Mean) | ||||
---|---|---|---|---|---|
Day 0 | Day 30 | Day 60 | Day 90 | Day 120 | |
1000mg Exposure | 107.6 | 130.7 | 137.9 | 135 | 142.2 |
1500mg Exposure | 128.1 | 128.1 | 128.6 | 138.2 | 144.2 |
500mg Exposure | 136.5 | 139.9 | 121.4 | 137.8 | 134 |
Placebo | 141.5 | 144.75 | 134.3 | 152 | 159.2 |
HOMA-IR is calculated from Fasting Glucose and Fasting Insulin (NCT00063232)
Timeframe: from baseline to 48 weeks
Intervention | unit (Mean) |
---|---|
Metformin | -3.3 |
Alanine transaminase <42 U/L is considered normal (NCT00063232)
Timeframe: from baseline to 48 weeks
Intervention | participants (Number) | |||
---|---|---|---|---|
changed to normal from abnormal | unchanged (normal at beginning) | unchanged (abnormal at beginning) | changed to abnormal from normal | |
Metformin | 9 | 4 | 12 | 1 |
Patients under went liver biopsy, metabolic profiling and imaging studies before and at the end 48 weeks of metformin (2000 mg/day) therapy. The primary endpoint is a three point improvement in the histological NASH activity index with a decrease in at least two of the component scores and no worsening of fibrosis or increase in Mallory bodies. (NCT00063232)
Timeframe: from baseline to 48 Weeks
Intervention | participants (Number) | |||
---|---|---|---|---|
improved (reduced) by greater or equal to 3 points | improved (reduced) by 1-2 points | no change | worsen (increased) | |
Metformin | 9 | 11 | 5 | 1 |
(NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | kg/m-squared (Mean) |
---|---|
Metformin | 1.3 |
Vitamin E | 2.1 |
Placebo | 1.9 |
Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2). (NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | units on a scale (Mean) |
---|---|
Metformin | -1.1 |
Vitamin E | -1.8 |
Placebo | -0.7 |
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | units on a scale (Mean) |
---|---|
Metformin | 4.0 |
Vitamin E | 6.0 |
Placebo | 5.6 |
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life. (NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | units on a scale (Mean) |
---|---|
Metformin | 5.4 |
Vitamin E | 7.6 |
Placebo | 5.4 |
(NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | IU/L (Mean) |
---|---|
Metformin | -21.5 |
Vitamin E | -22.8 |
Placebo | -20.4 |
Change in alpha-Tocopherol (NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | mg/L (Mean) |
---|---|
Metformin | -0.5 |
Vitamin E | 9.4 |
Placebo | -0.9 |
Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning. This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning. (NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | participants (Number) |
---|---|
Metformin | 22 |
Vitamin E | 22 |
Placebo | 10 |
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis. This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis. (NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | participants (Number) |
---|---|
Metformin | 22 |
Vitamin E | 18 |
Placebo | 19 |
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation. This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation. (NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | participants (Number) |
---|---|
Metformin | 23 |
Vitamin E | 22 |
Placebo | 20 |
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis. This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis. (NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | participants (Number) |
---|---|
Metformin | 26 |
Vitamin E | 27 |
Placebo | 19 |
The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment. (NCT00063635)
Timeframe: baseline and 96 weeks
Intervention | participants (Number) |
---|---|
Metformin | 9 |
Vitamin E | 15 |
Placebo | 10 |
The effect of exenatide and pioglitazone on liver fat content after one year of treatment in patients with type 2 diabetes. (NCT01432405)
Timeframe: one year
Intervention | percent of liver fat (Mean) |
---|---|
Pioglitazone and Exenatide | 4.7 |
Pioglitazone | 6.5 |
the effect of the intervention on plasma adiponectin levels. (NCT01432405)
Timeframe: one year
Intervention | microgram per ml (Mean) |
---|---|
Pioglitazone and Exenatide | 23.2 |
Pioglitazone | 15.8 |
Absolute Change in MRI-Proton Density Fat Fraction (expressed as percent fat in the liver) from baseline to week 12 (NCT02653300)
Timeframe: Two timepoints: Baseline (week 0) and Week 12
Intervention | percentage fat in the liver (Mean) | ||
---|---|---|---|
MRPDFF (%) at baseline | MR PDFF (%) at Week 12 | Absolute Mean Change in MR PDFF (%) from Baseline | |
Oral Insulin | 21.3 | 14.4 | -6.9 |
Mean fibrosis score (severity scale of liver fibrosis) measured at baseline and week 12. Fibrosis Score CAP measures the amount of steatosis (fatty change) in the liver. The CAP score is measured in decibels per meter (dB/m). It ranges from 100 to 400 dB/m with higher values indicating more fatty change (NCT02653300)
Timeframe: Two timepoints: Baseline (week 0) and Week 12
Intervention | dB/M (Mean) | |
---|---|---|
Mean Fibrosis Score at Baseline | Mean Fibrosis Score at week 12 | |
Oral Insulin | 338.5 | 315.5 |
Mean Transient elasticity, measured in kPA (kilo Pascal), (NCT02653300)
Timeframe: Two timepoints: Baseline (week 0) and Week 12
Intervention | kPa (Mean) | |
---|---|---|
Baseline | Week 12 | |
Oral Insulin | 8.6 | 7.4 |
42 reviews available for metformin and Fatty Liver
Article | Year |
---|---|
Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review.
Topics: Body Mass Index; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fatty Liver; Femal | 2017 |
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
Topics: Bariatric Surgery; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Me | 2014 |
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Re | 2013 |
The role of medications for the management of patients with NAFLD.
Topics: Antioxidants; Fatty Liver; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Me | 2014 |
The therapy of insulin resistance in other diseases besides type 2 diabetes.
Topics: Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic | 2014 |
[Non-alcoholic fatty liver disease--new view].
Topics: Biopsy; Causality; Comorbidity; Disease Progression; Fatty Liver; Humans; Hyperglycemia; Insulin Res | 2008 |
Current and emerging therapies in nonalcoholic fatty liver disease.
Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type | 2009 |
Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.
Topics: Acetylcysteine; Adult; Alanine Transaminase; Aspartate Aminotransferases; Carnitine; Child; Dietary | 2009 |
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Topics: Fatty Liver; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metf | 2009 |
Insulin resistance and response to antiviral therapy in chronic hepatitis C: mechanisms and management.
Topics: Animals; Antiviral Agents; Diabetes Mellitus, Type 2; Fatty Liver; Glucose Clamp Technique; Hepatiti | 2010 |
Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.
Topics: Adipose Tissue; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Discovery; Fatty Liver; Genetic Pr | 2010 |
Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin; Metformin; Randomized Controlled Trials as Topic; | 2010 |
Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
Topics: Clinical Trials as Topic; Fatty Liver; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Met | 2010 |
[Fatty liver and its clinical management in obese adolescents].
Topics: Adiponectin; Adolescent; Apoptosis; Biomarkers; Chemokines; Disease Progression; Fatty Liver; Fibros | 2011 |
Use of metformin in pediatric age.
Topics: Adolescent; Antipsychotic Agents; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty | 2011 |
Nonalcoholic fatty liver disease and type 2 diabetes mellitus: the hidden epidemic.
Topics: Bariatric Surgery; Biopsy; Diabetes Mellitus, Type 2; Disease Progression; Exercise; Fatty Liver; Hu | 2011 |
Management of metabolic syndrome in children and adolescents.
Topics: Adolescent; Antioxidants; Cardiovascular Diseases; Child; Cholesterol, HDL; Cholesterol, LDL; Diabet | 2011 |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; | 2011 |
The role of metformin in the management of NAFLD.
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin | 2012 |
Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin.
Topics: Adipokines; Androgens; Endocrine System; Fatty Acids, Nonesterified; Fatty Liver; Female; Hormones; | 2012 |
Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease.
Topics: Animals; Fatty Liver; Humans; Hypoglycemic Agents; Liver; Metformin; Non-alcoholic Fatty Liver Disea | 2012 |
Pharmacologic therapy for nonalcoholic fatty liver disease in adults.
Topics: Adult; Animals; Disease Progression; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibi | 2013 |
Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD.
Topics: Carcinoma, Hepatocellular; Child; Fatty Liver; Humans; Hypoglycemic Agents; Liver Neoplasms; Metform | 2013 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Topics: Adult; Animals; Biochemical Phenomena; Biochemistry; Biopsy, Needle; Clinical Trials as Topic; Disea | 2003 |
Nonalcoholic fatty liver disease in the pediatric population.
Topics: Adolescent; Alanine Transaminase; Child; Fatty Liver; Female; Histocytochemistry; Humans; Hypoglycem | 2004 |
Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment.
Topics: Antioxidants; Cholagogues and Choleretics; Cytoprotection; Enzyme Inhibitors; Fatty Liver; Humans; H | 2004 |
The fatty liver and insulin resistance.
Topics: Adiponectin; Adipose Tissue; Alanine Transaminase; Animals; Antiretroviral Therapy, Highly Active; C | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fa | 2005 |
Review article: the treatment of fatty liver disease associated with the metabolic syndrome.
Topics: Adult; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metabolic Syndrome; | 2005 |
[Therapeutic options for nonalcoholic fatty liver disease and steatohepatitis].
Topics: Diet Therapy; Exercise Therapy; Fatty Liver; Fatty Liver, Alcoholic; Humans; Liver Cirrhosis; Liver | 2005 |
Review article: Drug therapy for non-alcoholic fatty liver disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Ascorbic Acid; Betaine; Cholagogues and Chol | 2006 |
Therapy of NAFLD: insulin sensitizing agents.
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Thiazolidinediones | 2006 |
Treatment of nonalcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Body Mass Index; Fatty Liver; Humans; Hypolipidemic Age | 2006 |
[Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
Topics: Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglit | 2006 |
Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.
Topics: Controlled Clinical Trials as Topic; Diet, Carbohydrate-Restricted; Fatty Liver; Humans; Hypoglycemi | 2006 |
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Fatty Liver; Humans; Hypoglycemic Agents; Insulin | 2007 |
Treatment of fibrosis in nonalcoholic fatty liver disease.
Topics: Adiponectin; Adipose Tissue; Animals; Antioxidants; Cytokines; Fatty Liver; Humans; Hypoglycemic Age | 2007 |
[Pathogenetic treatment of non-alcoholic steatohepatitis: arguments, efficacy, safety].
Topics: Exercise Therapy; Fatty Acids; Fatty Liver; Humans; Hypoglycemic Agents; Immunologic Factors; Metfor | 2007 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metform | 2007 |
Metformin beyond diabetes: new life for an old drug.
Topics: Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglyc | 2006 |
36 trials available for metformin and Fatty Liver
Article | Year |
---|---|
Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study.
Topics: Blood Glucose; Carotid Intima-Media Thickness; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV In | 2023 |
The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat.
Topics: Adolescent; Adult; Case-Control Studies; Child; Fatty Liver; Female; Growth Differentiation Factor 1 | 2021 |
Metformin for Rapidly Maturing Girls with Central Adiposity: Less Liver Fat and Slower Bone Maturation.
Topics: Adiposity; Fatty Liver; Female; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Life Style; Metfor | 2018 |
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Topics: Adipokines; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2 | 2013 |
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.
Topics: Adiponectin; Adult; Aged; Alanine Transaminase; Blood Glucose; Body Mass Index; Body Weight; C-React | 2013 |
Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Carnitine; DNA | 2014 |
Effect of piglitazone and metformin on retinol-binding protein-4 and adiponectin in patients with type 2 diabetes mellitus complicated with non-alcohol fatty acid liver diseases.
Topics: Adiponectin; Adult; Aged; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Male; Metformin; M | 2014 |
Effect of vildagliptin on hepatic steatosis.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration | 2015 |
Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial.
Topics: Adipose Tissue; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liv | 2015 |
High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diastole; Diet; Exercise; E | 2016 |
Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Biopsy; Body Mass Index; Child; Fatty | 2008 |
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Body Weight; Child; | 2009 |
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Body Weight; Child; | 2009 |
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Body Weight; Child; | 2009 |
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Body Mass Index; Body Weight; Child; | 2009 |
The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.
Topics: Adult; Body Mass Index; Diabetes Mellitus, Type 2; Exercise; Fatty Liver; Female; Glycated Hemoglobi | 2009 |
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.
Topics: Adult; Biopsy; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged | 2009 |
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.
Topics: Adult; Biopsy; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged | 2009 |
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.
Topics: Adult; Biopsy; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged | 2009 |
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.
Topics: Adult; Biopsy; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Middle Aged | 2009 |
Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.
Topics: Adolescent; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Child; Drug The | 2008 |
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease.
Topics: Adult; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Liver; Fem | 2010 |
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.
Topics: Adolescent; Alanine Transaminase; Child; Double-Blind Method; Fatty Liver; Female; Humans; Hypoglyce | 2010 |
Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Biopsy; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Fatty L | 2009 |
Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study.
Topics: Adult; Body Mass Index; Diet; Fatty Liver; Female; Humans; Hypoglycemic Agents; Male; Metformin; Non | 2010 |
Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program.
Topics: Adult; Alanine Transaminase; Biomarkers; Diabetes Mellitus; Fatty Liver; Female; Glucose Intolerance | 2010 |
Metformin: a therapeutic option for treating nonalcoholic fatty liver disease.
Topics: Diet; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Liver; Female; Follow-Up | 2010 |
Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.
Topics: Adult; Aged; Arteries; Blood Flow Velocity; Blood Glucose; Fatty Liver; Female; Humans; Hypoglycemic | 2011 |
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.
Topics: Adolescent; Alanine Transaminase; Antioxidants; Child; Double-Blind Method; Fatty Liver; Female; Hum | 2011 |
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biopsy; Drug Therapy, Combination; | 2011 |
Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
Topics: Alanine Transaminase; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Fema | 2012 |
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, | 2011 |
Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies.
Topics: Adult; alpha-2-HS-Glycoprotein; Biomarkers; Cross-Sectional Studies; Dose-Response Relationship, Dru | 2012 |
Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?
Topics: Adiponectin; Adult; Aged; Biomarkers; Blood Glucose; Down-Regulation; Fatty Liver; Female; Hemodynam | 2012 |
Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Exercise; Fats; Fatty Acids, Monounsaturated; Fatty Liver; F | 2012 |
Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Disease Progression; Fatty Liver; Fema | 2012 |
Metformin superior to low‑fat diet for the treatment of patients with nonalcoholic fatty liver disease and/or steatohepatitis.
Topics: Adult; Diet, Fat-Restricted; Fatty Liver; Female; Humans; Male; Metformin; Middle Aged; Non-alcoholi | 2012 |
Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Antioxidants; Aspartate Aminotransferases; | 2012 |
Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. A pilot study.
Topics: Adult; Alanine Transaminase; Blood Flow Velocity; Diet; Fatty Liver; Female; Hemodynamics; Humans; H | 2004 |
A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.
Topics: Adolescent; Blood Glucose; Child; Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistan | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Topics: Adult; Aged; Alanine Transaminase; Antioxidants; Aspartate Aminotransferases; Biopsy; Body Mass Inde | 2005 |
Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Diet Therapy; Exercise Therapy; Fatty Live | 2008 |
88 other studies available for metformin and Fatty Liver